Intech Biopharm Corporation
Taipei Exchange 6461.TWO
Intech Biopharm Corporation Operating Income Margin for the year ending December 31, 2023: -1,239.87%
Intech Biopharm Corporation Operating Income Margin is -1,239.87% for the year ending December 31, 2023, a 3.82% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
-
Intech Biopharm Corporation Operating Income Margin for the year ending December 31, 2022 was -1,289.11%, a -77.68% change year over year.
-
Intech Biopharm Corporation Operating Income Margin for the year ending December 31, 2021 was -725.51%, a 34.44% change year over year.
-
Intech Biopharm Corporation Operating Income Margin for the year ending December 31, 2020 was -1,106.60%.
Key data
| Date | Operating Income Margin | EBT Margin | Net Income Margin | EBITDA Margin |
|---|
Market news
Loading...
Taipei Exchange: 6461.TWO
| CEO | Mr. Wei-Shiu Wu |
| IPO Date | July 15, 2014 |
| Location | |
| Headquarters | No. 36, Ruiguang Road |
| Employees | 82 |
| Sector | Health Care |
| Industries | |
Description
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email